Personalizing Pediatric Cancer Care

Innovation Through Collaboration

A hybrid summit March 10-11, 2022

HOSTED BY THE CANCER CENTER AND THE DEPARTMENT OF PATHOLOGY & LABORATORY MEDICINE

Children's Hospital of Philadelphia®

Personalizing Pediatric Cancer Care

INFORMATION FOR IN-PERSON ATTENDEES

Summit location:

The Rittenhouse Hotel 210 W. Rittenhouse Square, Philadelphia, PA 19103

Parking:

Valet parking is available at the Rittenhouse Hotel. There are also parking garages and public parking lots within walking distance.

Poster Abstract Presentation March 10, 2022, at 6 p.m.



Hosted by Children's Hospital of Philadelphia, ranked the #1 pediatric cancer program in the nation for two years in a row by *U.S. News & World Report.*



With our guiding principle of "innovation through collaboration," we at Children's Hospital of Philadelphia are thrilled to welcome you to our inaugural summit, "Personalizing Pediatric Cancer Care," where world-class experts will convene to present on scientific advancements, unpublished data, and precision medicine oncology breakthroughs. From new and novel laboratory diagnostics to cutting-edge therapeutics, to patient advocacy — you'll be joining other physicians, care providers, researchers, clinical geneticists, and laboratory leaders seeking to advance precision-based medicine in pediatric cancer care.

Topics will include: Hematological malignancies • CNS malignancies • Solid malignancies • Cancer predisposition • Advances in lab diagnostics and genetics • FDA/regulatory updates • Patient advocacy

We look forward to you joining us at this inaugural summit!

John Maris, MD Children's Hospital of Philadelphia

Marilyn Li, MD, Children's Hospital of Philadelphia

Event Co-chairs

Personalizing Pediatric Cancer Care Innovation Through Collaboration

PROGRAM

Please note: All times listed are Eastern Time Itinerary subject to change

| Thursday, March 10, 2022 | | 11:15 a.m.–11:45 | |
|--|---|---|--|
| 7 –7:45 a.m. 7:45 –8 a.m. | Breakfast Welcome John Maris, MD, | | Medulloblastoma Liquid Biopsies: Clinical and Biological Applications Paul Northcott, PhD |
| | and Marilyn Li, MD | 11:45–1:00 p.m. | Lunch 20 minute Lunch & Learn with |
| Session 1: Leukemia Sarah Tasian, MD, and Kathrin Bernt, MD, Co-Chairs | | | Dr. David Solomon sponsored by Illumina Genome-wide DNA Methylation Profiling: Transforming pathology |
| 8 –8:30 a.m. | Targeting High-Risk Leukemia with Protein Degradation Charles Mullighan, MD | from a microscopic impression to an exact tumor classification | |
| 8:30–9 a.m. | Precision Targeting of Aberrant Transcription in Leukemia Kathrin Bernt, MD | Session 3: Regulatory, Lab Diagnostics 1, Advocacy John Maris, MD, Chair | |
| 9–9:30 a.m. | Traveling Along the Bench-to- Bedside Road of AML CAR T-Cell Immunotherapy Sarah Tasian, MD | 1:00–1:30 p.m. | Leveraging Changes in the Regulatory Landscape for Pediatric Cancer Drug Development to Accelerate Precision Oncology for Children |
| 9:30 –10 a.m. | Therapeutic Targeting of Non- Hematopoietic Antigens in AML Soheil Meshinchi, MD, PhD | 1:30-2 p.m. | Greg Reaman, MD Recent Advancements in |
| 10 –10:15 a.m. | Break | Ŧ | Cancer Diagnostics Todd Druley, MD, PhD |
| Session 2: Brain Tumors Michael Fisher, MD, and Tom DeRaedt, PhD, Co-Chairs | | 2–2:30 p.m. | Kinase-Altered Mesenchymal Spindle Cell Tumors: Algorithmic Approaches for Diagnosis and Therapeutic Target Identification |
| | Mapping Childhood Brain Tumors onto Normal Brain Development for Target Identification Stefan Pfister, MD Data Platforms and Networks: | 2:30–3 p.m. | Lea Surrey, MD Beyond RACE for Children Act: Give Kids a Chance Act to Establish Combinations of Novel Therapies in Pediatric Study Plans Nancy Goodman, JD |
| | Patient-Centered Discovery Ecosystems for Accelerated | 3 –3:15 p.m. | Break |
| | Discovery Adam Resnick, PhD | | |

Session 4: Solid Tumors 9:30–10 a.m. Genetic Susceptibility to Yael Mosse, MD, and Neuroblastoma: Recent Discoveries Patrick Grohar, MD, Co-Chairs and Clinical Implications Sharon Diskin, PhD 3:15–3:45 p.m. ALK Inhibition for ALK-Driven **Childhood Cancers: A Paradigm for** 10-10:15 a.m. **Break Precision Medicine** Yael Mosse, MD Session 6: Lab Diagnostics 2 **Genomic Analysis in** 3:45-4:15 p.m. Marilyn Li, MD, and Osteosarcoma John Maris, MD, Co-Chairs Alejandro Sweet-Cordero, MD 4:15–4:45 p.m. Interim Report from the 10:15-10:45 a.m. Clinical Utility of Mutational GAIN/iCat2 Study **Signatures in Childhood Cancer** Katie Janeway, MD Adam Shlien, PhD 4:45–5:15 p.m. NCI-COG Pediatric MATCH Trial: 10:45–11:15 a.m. Transcription Deregulation **Lessons Learned and Next Steps Caused by Somatic Non-coding** Will Parsons, MD, PhD Variants in Pediatric Cancer 5:15-5:45 p.m. **Development and Clinical** Jinghui Zhang, PhD **Translation of EWS-FLI1** 11:15–11:45 a.m. An Integrated Multi-Omics **Targeted Therapies Approach for Precision** Patrick Grohar, MD **Cancer Care** Marilyn Li, MD 6 p.m. **Reception & Poster Session Discussion and Wrap-up** 11:45 a.m.-12:15 p.m. Marilyn Li, MD, and Friday, March 11, 2022

John Maris, MD

7–8 a.m. Breakfast

Session 5: Cancer Predisposition Suzanne MacFarland, MD, and Kristin Zelley, MS, CGC, Co-Chairs

| 8 –8:30 a.m. | Cancer Predisposition |
|----------------|--|
| | Syndromes – Moving from |
| | Syndrome to Spectrum |
| | Christian Kratz, MD |
| 8:30–9 a.m. | Li-Fraumeni Syndrome: |
| | Examining the Evolution of |
| | Precision Prediction, Prevention |
| | and Therapy in Cancer |
| | Predisposition |
| | David Malkin, MD |
| 9:00–9:30 a.m. | Next Gen Clinical Cancer Genetics Kenan Onel. MD. PhD |

SPEAKERS



Kathrin Bernt, MD, Children's Hospital of Philadelphia



Todd Druley, MD, PhD, ANGLE Biosciences



Patrick Grohar, MD, PhD, Children's Hospital of Philadelphia



Marilyn Li, MD, Children's Hospital of Philadelphia



John Maris, MD, Children's Hospital of Philadelphia



<u>Charles Mullighan,</u> <u>MD,</u> St. Jude Children's Research Hospital



<u>Will Parsons, MD,</u> <u>PhD,</u> Texas Children's Hospital



Adam Resnick, PhD, Children's Hospital of Philadelphia



Lea Surrey, MD, Children's Hospital of Philadelphia



Jinghui Zhang, PhD, St. Jude Children's Research Hospital





<u>Mike Fisher, MD,</u> Children's Hospital of Philadelphia

Suzanne MacFarland,

MD, Children's Hospital

of Philadelphia

Cancer Center

Soheil Meshinchi,

MD, PhD, Fred Hutch

Hospital of Philadelphia

Thomas DeRaedt,

PhD, Children's



Katie Janeway, MD, Boston Children's Hospital







Adam Shlien, PhD, The Hospital for Sick Children, Toronto



<u>Alejandro Sweet-</u> <u>Cordero, MD,</u> University of California, San Francisco



Sharon Diskin, PhD, Children's Hospital of Philadelphia



Nancy Goodman, JD,

Kids v Cancer



Christian Kratz, MD, Hannover Medical School, Hannover, Germany



David Malkin, MD, the Hospital for Sick Children, Toronto, Canada



<u>Yael Mosse, MD,</u> Children's Hospital of Philadelphia



Kenan Onel, MD, PhD, Sema4



<u>Greg Reaman, MD,</u> U.S. Food and Drug Administration



David Solomon, MD, PhD University of California, San Francisco



<mark>Sarah Tasian, MD,</mark> Children's Hospital of Philadelphia



Stefan Pfister, MD,

Cancer Center (KiTZ),

Heidelberg, Germany

Hopp Children's

THANK YOU TO OUR SPONSORS

illumina



labcorp | Oncology



U NOVARTIS





Supported by a grant from Pfizer Inc.

NOTES









Pathology & Laboratory Medicine